About this item:

786 Views | 1,164 Downloads

Author Notes:

Correspondence to: Dr. Sheng-Han Kuo, Department of Neurology,College of Physicians and Surgeons, Columbia University, 710 West168th Street, 3rd floor, New York, NY 10032, USA; sk3295@columbia.edu

Relevant conflicts of interest/financial disclosures: Nothing to report.

Full financial disclosures and author roles may be found in the online version of this article.

Subjects:

Research Funding:

This work was supported by the American Academy of Neurology Clinical Research Training Fellowship, Parkinson Disease Foundation, the National Institute of Neurological Disorders and Stroke (K08 NS083738), the Louis V. Gerstner Jr. Scholarship, the American Parkinson's Disease Association, and the Rare Disease Clinical Research Network (RDCRN) (RC1NS068897).

Keywords:

  • coenzyme Q10
  • statins
  • spinocerebellar ataxias
  • neurodegeneration

Coenzyme Q10 and spinocerebellar ataxias

Show all authors Show less authors

Tools:

Journal Title:

Movement Disorders

Volume:

Volume 30, Number 2

Publisher:

, Pages 214-220

Type of Work:

Article | Post-print: After Peer Review

Abstract:

The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association.

Copyright information:

© 2014 International Parkinson and Movement Disorder Society

Export to EndNote